Ondine Biomedical Inc. Achieves Commercial Adoption of Steriwave in NHS Hospitals

Ondine Biomedical Inc. has announced the first commercial adoption of its Steriwave light-activated antimicrobial technology by two NHS hospitals, aiming to combat antimicrobial resistance (AMR) and reduce surgical infections. Mid Yorkshire Teaching NHS Trust has integrated Steriwave as a standard-of-care for orthopedic patients to decrease surgical site infections (SSIs), particularly in hip and knee surgery at Pontefract and Pinderfields NHS Hospitals.

Dr. Stuart Bond highlighted the technology's significance in improving patient outcomes, while Ondine's CEO, Carolyn Cross, lauded the NHS for setting a global benchmark in antibiotic stewardship. The technology's effective, resistance-free nature compared to traditional antibiotics marks a pivotal achievement in healthcare.

Additionally, a health economic analysis sponsored by Ondine Biomedical, Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire & Humber is underway, aiming to support the broader adoption of Steriwave across the NHS. The technology has already demonstrated substantial cost savings and reduction in post-surgical infection rates in other countries, reinforcing its potential within the NHS framework.